A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors

NCT03196297 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Haemostasis
Haemophilia A

Interventions

DRUG: Concizumab
DRUG: Turoctocog alfa

Sponsor

Novo Nordisk A/S